Last ¥2,942 JPY
Change Today +5.00 / 0.17%
Volume 461.0K
4578 On Other Exchanges
Symbol
Exchange
Tokyo
Berlin
OTC US
As of 2:00 AM 04/18/14 All times are local (Market data is delayed by at least 15 minutes).

otsuka holdings co ltd (4578) Snapshot

Open
¥2,927
Previous Close
¥2,937
Day High
¥2,943
Day Low
¥2,912
52 Week High
05/14/13 - ¥3,630
52 Week Low
10/9/13 - ¥2,606
Market Cap
1.6T
Average Volume 10 Days
1.7M
EPS TTM
¥319.76
Shares Outstanding
557.8M
EX-Date
03/27/14
P/E TM
9.2x
Dividend
¥65.00
Dividend Yield
2.21%
Current Stock Chart for OTSUKA HOLDINGS CO LTD (4578)

Related News

No related news articles were found.

otsuka holdings co ltd (4578) Related Businessweek News

View More BusinessWeek News

otsuka holdings co ltd (4578) Details

Otsuka Holdings Co., Ltd, together with its subsidiaries, manufactures and sells health care products world wide. The company operates in four segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Other. The Pharmaceuticals segment is involved in the research and development, production, and sale of therapeutic drugs in the areas of central nervous system, oncology, cardiovascular system, gastroenterology, respiratory system, infectious disease, ophthalmology, dermatology, allergies, urology, and others; intravenous and enteral nutrition solutions; influenza diagnostic agents, Helicobacter pylori test kits, and other products; and apheresis device for leukocyte adsorption, drug-eluting stents, and other products, as well as provides contract manufacturing services. The Nutraceuticals segment provides functional foods and beverages, such as electrolyte supplement drinks, carbonated nutritional drinks, oral rehydration solution, soy soda beverages, soy bars, nutritionally balanced foods, supplements, and nutritional biscuits; OTC and quasi-drugs, including multi-vitamin nutrient tonic and ointment for skin conditioning; and men’s skincare products. The Consumer Products segment offers beverages, foods, and alcoholic beverages, such as mineral water, carbonated vitamin drink, straight tea, and instant curry in plastic pouch. The Other segment provides functional and fine chemicals for the automotive, electrical, electronic, and building materials sectors; and transport and warehousing services for pharmaceuticals, foods, and beverages. This segment also develops, manufactures, and markets optical evaluation/inspection equipment, liquid crystal display panel materials, and finished products, as well as medical equipment and clinical diagnostic equipment. The company was founded in 1921 and is headquartered in Tokyo, Japan.

25,330 Employees
Last Reported Date: 06/28/13
Founded in 1921

otsuka holdings co ltd (4578) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

otsuka holdings co ltd (4578) Key Developments

Otsuka Pharmaceutical Co. Ltd. Announces Regulatory Approval for Pharmacological Treatment of Autosomal Dominant Polycystic Kidney Disease

Otsuka Pharmaceutical Co. Ltd. announced that it has obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD. Samsca was developed over the past 26 years by the efforts of many researchers in Otsuka's Tokushima, Japan research facility. It is currently used in 14 countries and territories around the world as an aquaretic drug, which facilitates excretion of only free water without electrolyte loss due to its antagonist action on vasopressin V(2) receptors. Upon a discovery that proliferation and enlargement of renal cysts are hindered by suppression of cAMP formation at vasopressin V(2) receptors(vi), Otsuka launched a new effort from 2004 to develop a drug for the rare disease ADPKD, in conjunction with world specialists including Dr. Vicente E. Torres of the Mayo Clinic in the U.S. In global clinical trials (the TEMPO 3:4 trial(vii)) conducted in 15 countries on more than 1,400 patients with ADPKD, Samsca was shown to significantly suppress the rate of increase in total kidney volume by approximately 50% more than a placebo. The results of these trials were published in November, 2012 in the New England Journal of Medicine.

Otsuka Holdings Co., Ltd. Presents at The 8th Annual Daiwa Investment Conference Tokyo 2014, Mar-03-2014

Otsuka Holdings Co., Ltd. Presents at The 8th Annual Daiwa Investment Conference Tokyo 2014, Mar-03-2014 . Venue: The Prince Park Tower Tokyo, 4-8-1, Shibakoen, Minato-ku, Tokyo 105-8563, Japan.

Otsuka Holdings Co., Ltd., Q3 2014 Earnings Call, Feb 13, 2014

Otsuka Holdings Co., Ltd., Q3 2014 Earnings Call, Feb 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4578:JP ¥2,942.00 JPY +5.00

4578 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4578.
View Industry Companies
 

Industry Analysis

4578

Industry Average

Valuation 4578 Industry Range
Price/Earnings 9.5x
Price/Sales 1.2x
Price/Book 1.1x
Price/Cash Flow 8.8x
TEV/Sales 0.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OTSUKA HOLDINGS CO LTD, please visit www.otsuka.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.